• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

ASH offers early look at updated SCD guidelines: Experts formulated >50 recommendations on sickle cell disease


The American Society of Hematology (ASH) previewed clinical guidelines on sickle cell disease (SCD) here, with the intention of releasing the full set of guidelines in 2019.

The chairs from each of the five SCD guideline panels — sickle cell disease-related transfusion support; sickle cell disease-related cardiopulmonary and kidney disease; sickle cell disease-related cerebrovascular disease; sickle cell disease-related pain; and stem cell transplantation for sickle cell disease — discussed a key recommendation from each of their panels at the ASH annual meeting.

These five SCD panels, which included more than 75 experts across the field, have formulated more than 50 recommendations on SCD. Some draft recommendations veer away from standard practice, or even address issues that haven’t been addressed in previous SCD guidelines.

For example, John F. Tisdale, MD, of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, pointed out that ASH is putting out the first set of guidelines addressing transplantation in SCD, and noted the stem cell transplantation panel’s recommendation of “transplantation at a younger age over transplantation at an older age.”


To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.